Transfer pricing at heart of Pfizer case
Shareholders allege that Pfizer has deliberately contributed to poor results at its Pakistan operations, thus diluting the value of the minority stakeholders’ shares
Reply to comment
Having read your article and the Court ruling a number of questions arise.
1. The last line of Court ruling states “disposed off” and Pfizer’s Company secretary states the issues sub-judice and a appeal is planned. This is a contradictory position. A employee is always going to find it difficult to defend unfair policies of his employer.
2. Why did court ordered examination by Ernest & Young find different then Company’s accountants KPMG? Was KMPG looking the other way as Arthur Anderson did in the Enron case.
3. In my opinion multinational pharmaceutical companies operations in thirld world countries should be monitored very tightly with respect to abuse of Intellectual Property Rights, financial & trade operations and corrupting of local human resources.
Ejaz